In a phase 3 clinical trial in Africa, RTS,S elicited modest protection against clinical malaria that correlated with CSP antibody and CD4+ T cell responses [6–8], suggesting that antibodies to sporozoites can mediate protection against malaria. Here, CD4 is linked to malaria.